MarketMoodz
Ovid Therapeutics' Epilepsy Data Sparks Rally, Pipeline Expansion
Ovid Therapeutics jumped on OV329 topline data showing favorable safety at 7 mg in drug-resistant epilepsies, with no treatment-related adverse events in that cohort. The company also unveiled a pipeline expansion to TSC seizures and infantile spasms and disclosed a $60 million private placement to fund key milestones into late 2028 (potentially 2029).
Key Takeaways
- OV329 topline safety favorable at 7 mg with no treatment-related adverse events in the 7 mg cohort
- Expansion of OV329 into TSC seizures and infantile spasms with PoC study expected in Q4 2026
- OV4071 Phase 1 clearance in Australia as a first-in-class oral KCC2 activator for neuropsychiatric symptoms in PD and Lewy body dementia
- Private financing of $60 million via 19.15 million shares at $2.01 and pre-funded warrants for 10.7 million shares at $2.009
- Cash and equivalents of $90.4 million as of 12/31/2025, runway into late 2028 (warrants could extend into 2029)
People Involved
- No specific individuals mentioned
Entities Involved
- Ovid Therapeutics Inc.Biotech company focusing on epilepsy therapies
- Australian Therapeutic Goods Administration (TGA)Regulatory agency that cleared OV4071 for Phase 1
MarketMoodz Analysis
The topline OV329 safety signal reinforces the case for a safer tolerability profile in drug-resistant epilepsies, potentially supporting broader PoC readouts in TSC seizures and infantile spasms and helping de-risk the program. The OV329 data, alongside OV4071’s regulatory clearance, positions Ovid to capitalize on near-term catalysts while maintaining flexibility through late-2028/2029 funding.
A private capital raise of $60 million reduces near-term dilution risk, extending the burn rate runway and giving management room to advance both OV329 and OV4071 milestones through 2028/2029. In the context of a volatile biotech space, the combination of a data-driven safety signal and a funded pathway to multiple milestones could attract investor interest, though outcomes remain contingent on upcoming PoC and Phase 1 results and competitive dynamics in epilepsy-focused biotech.
Source: Original Article